Lucius Pharmaceuticals – Oncology and Hepatitis Medicines
Lucius
Lucius Pharmaceuticals is a pharmaceutical company based in Laos, in the Xaythany district of the capital, Vientiane. It makes generic medicines for cancer and other serious diseases.
Targeted oncology is Lucius's main focus. Its portfolio includes generics of modern kinase inhibitors and other targeted drugs, among them molecules approved in the US and Europe only in recent years, such as adagrasib, repotrectinib and lazertinib. According to the company, as of June 2024 it had registered 54 anti-cancer drugs and more than 200 generics in other classes.
Beyond oncology, the company's website lists haematology, cardiology, endocrinology, nephrology, neurology, rheumatology and other areas. Lucius reports partners in Thailand, Indonesia, Cambodia, Vietnam, the Philippines, Malaysia and Sri Lanka, as well as in Türkiye, Japan and China.
Unifarm carries Lucius oncology medicines: LuciOsim (osimertinib), LuciAbe (abemaciclib), LuciRibo (ribociclib), LuciOlap (olaparib), LuciCaboz (cabozantinib), LuciEncor (encorafenib), LuciAda (adagrasib), LuciRepo (repotrectinib) and more — see the full list below.